

# How Drug Usage During Labor and Delivery Affects Infant Health: A Predictive Analysis of APGAR5 Scores\*

!!! MAIN RESULTS !!!

Yunkyung Ko

November 26, 2024

First sentence. Second sentence. Third sentence. Fourth sentence.

## Table of Contents

<b>1</b>	<b>Introduction</b>	<b>2</b>
<b>2</b>	<b>Data</b>	<b>2</b>
2.1	Overview . . . . .	2
2.2	Measurement . . . . .	3
2.3	Outcome variables . . . . .	4
2.4	Predictor variables . . . . .	4
2.5	Correlation between predictor variables . . . . .	11
<b>3</b>	<b>Model</b>	<b>12</b>
3.1	Model set-up . . . . .	13
<b>4</b>	<b>Results</b>	<b>16</b>
4.1	Results from examining the analysis dataset . . . . .	16
4.2	Results from the prediction model . . . . .	19
<b>5</b>	<b>Discussion</b>	<b>20</b>
5.1	Pharmaceutical companies should focus on optimizing antenatal corticosteroid formulations . . . . .	20

\*Code and data are available at: [https://github.com/koyunkyung/infant\\_health](https://github.com/koyunkyung/infant_health).

5.2	Pharmaceutical companies, policymakers, and healthcare providers should collaborate to develop targeted antibiotics and enforce evidence-based protocols . . .	22
5.3	Third discussion point . . . . .	27
5.4	Limitations of the study and directions for future research . . . . .	31
<b>A</b>	<b>Appendix</b>	<b>34</b>
<b>B</b>	<b>Additional data details</b>	<b>34</b>
<b>C</b>	<b>Model details</b>	<b>34</b>
C.1	Posterior predictive check . . . . .	34
C.2	Diagnostics . . . . .	35
	<b>References</b>	<b>36</b>

## 1 Introduction

Overview paragraph

Estimand paragraph

Results paragraph

Why it matters paragraph

Telegraphing paragraph: The remainder of this paper is structured as follows. Section 2....

## 2 Data

### 2.1 Overview

We use the ‘2023 Natality Data for the United States’ to analyze the relationship between drug treatments administered to infants and their health outcomes. Provided by NBER and sourced from the National Center for Health Statistics (National Bureau of Economic Research (NBER) 2023), this dataset contains 3,605,081 live birth statistics across the U.S., including demographic details, health metrics, and geographical breakdowns by state and country (Centers for Disease Control and Prevention (CDC) and National Center for Health Statistics (NCHS) 2023). To represent treatments directly affecting the infant, variables under the category of ‘Characteristics of Labor and Delivery’ were selected, which capture medical interventions administered to the mother or infant during the critical period of childbirth (Centers for Disease Control and Prevention (CDC) 2016). Six different types of treatments are under this category, which are labor induction, augmentation, the use of steroids, antibiotics, chorioamnionitis, and anesthesia (Centers for Disease Control and Prevention (CDC)

and National Center for Health Statistics (NCHS) 2023). For the representation of infant health outcomes, the ‘APGAR5’ variable was selected, which shows the 5-minute Apgar score, a widely recognized indicator of an infant’s immediate health status post-delivery (Medical News Today 2024).

To ensure a balanced distribution of observations across all Apgar5 score groups, we applied stratified random sampling and designated the sample size per group as 2,000. In addition, for data quality, we standardized the treatment measuring variables, containing respondents’ answers of “Yes”, “No”, or “Unknown”, into binary numerical variables. Then, the variables were converted into factors to prepare the data for predictive modeling (Analytics Vidhya 2015), and split into training and testing sets to support machine learning workflows (Jason Brownlee 2019).

In performing the analysis, we utilized the statistical programming language R (R Core Team 2023) and several R packages. `tidyverse` (Wickham et al. 2019) was used for data manipulation, and `ggplot2` (Wickham 2016) was used for visualizing results in graphical methods. `randomForest` (Andy Liaw and Matthew Wiener 2002) and `caret` (Kuhn and Max 2008) were used for Random Forest modeling while `rstanarm` (Goodrich et al. 2024) was used for Bayesian linear modeling in the process of generating predictions.

## 2.2 Measurement

The data transforms the phenomenon of infant health status into data, defining quantifiable factors that can capture the complex impacts of maternal and neonatal pharmacological interventions (National Bureau of Economic Research (NBER) 2023). The transformation is achieved through the collection of information on various treatments and conditions experienced during labor and delivery, such as steroid use, chorioamnionitis, antibiotics, and anesthesia, among others (Centers for Disease Control and Prevention (CDC) and National Center for Health Statistics (NCHS) 2023). These variables, which were recorded through surveys or medical records, uses checkboxes or scales that allow for quantification (Centers for Disease Control and Prevention (CDC) 2016). Errors such as inconsistencies in how data is recorded can arise during this kind of measurement process (Alexander 2023). For instance, subjective interpretations of checkbox responses or variability in medical record documentation can lead to measurement error (HealthKnowledge 2024). These errors may result from differences in definitions of treatments across facilities or the accuracy of self-reported information in surveys (HealthKnowledge 2024).

The 5-minute Apgar score itself, is also a simplified numerical representation of an infant’s health, which may overlook the complexities of their condition. While useful for rapid clinical decision-making, the Apgar score may fail to capture nuanced aspects of an infant’s condition, such as underlying metabolic imbalances, subtle neurological issues, or long-term impact of perinatal complications (American Academy of Pediatrics 2006).

By structuring these variables into categorical or numerical forms, the data can be analyzed and used to model the relationship between treatments and the APGAR5 score. Specifically, drug usage during labor and delivery was encoded as binary variables (Section 2.4). However, this has a limitation that it disregards the quantitative intensity, dosage, or frequency of drug administration, leading to incomplete modeling of the treatment’s impact (GeeksforGeeks n.d.). This simplification may also amplify noise in the data by grouping dissimilar observations into the same category, reducing the model’s ability to detect subtle relationships (GeeksforGeeks n.d.).

## 2.3 Outcome variables

### 2.3.1 Apgar Score: a measure the infant’s chance of surviving the first year of life

The Apgar score is a measure of the need for resuscitation (Centers for Disease Control and Prevention (CDC) and National Center for Health Statistics (NCHS) 2023) to the infant, which is “the act of bringing someone back to life or waking them” (Cambridge University Press n.d.). It is a test given to newborns soon after birth (5 minutes) to check ‘Appearance(skin color)’, ‘Pulse(heart rate)’, ‘Grimace response(reflexes)’, ‘Activity(muscle tone)’, ‘Respiration(breathing rate and effort)’ (KidsHealth from Nemours n.d.). Each is rated on a scale of 0 to 2, with 2 being the best score (KidsHealth from Nemours n.d.). Apgar scores range from 0 to 10, with a score of 7 or higher indicating that the neonate is in good to excellent physical condition (Centers for Disease Control and Prevention (CDC) and National Center for Health Statistics (NCHS) 2023).

Figure 1 shows that the majority of infants in the raw dataset achieve a high APGAR5 score, clustering around 9 and 10. Very few observations exist for lower scores, reflecting rare instances of significant distress at birth. Even after filtering the dataset by selecting the relevant variables for analysis and removing the NA values, Figure 2 shows that the observations are overly clustered around high APGAR5 scores.

Therefore, to ensure a balanced analysis (Jason Brownlee 2020), the data was refined to achieve a more even distribution of observations across APGAR5 scores. Based on the lowest observation count of 2,065 in the original distribution, the number of observations for each APGAR5 score was set to 2,000 as shown in Figure 3. Random sampling was used for respective score groups to ensure a fair distribution across all score levels (Jason Brownlee 2020).

## 2.4 Predictor variables

All of the predictor variables used in the analysis are classified under the same category, which is the ‘Characteristics of labor and delivery’ (Centers for Disease Control and Prevention (CDC) and National Center for Health Statistics (NCHS) 2023). This item, which contains 6 separate checkboxes that the respondent can choose from, allows for the reporting of more




Figure 1: The distribution of APGAR5 scores across the entire observation in the original dataset **Note:** Unknown or unreported observations were excluded so that the distribution could be clearly visualized




Figure 2: The distribution of APGAR5 scores across the filtered observation in analysis dataset, which selected the relevant variables and removed the NA values

	0	1	2	3	4	5	6	7	8	9	10
Count	2000	2000	2000	2000	2000	2000	2000	2000	2000	2000	2000

Figure 3: The distribution of APGAR5 scores across the filtered observation in analysis dataset

than one characteristic and includes a choice of “None of the above” (Centers for Disease Control and Prevention (CDC) and National Center for Health Statistics (NCHS) n.d.).

### 2.4.1 Number of Treatments Used During Delivery and Labor

Figure 4 shows that the majority of observations involve 0 to 2 treatments during labor and delivery, with a steep decline in counts for 3 or more treatments. Most births reported in this dataset occur with minimal medical intervention, and higher number of treatments are relatively rare.




Figure 4: The distribution of observations across different number of treatments used during delivery and labor

### 2.4.2 Type of Treatments Used During Delivery and Labor

Figure 5 shows that the distribution of treatment types varies significantly, with anesthesia being the most commonly recorded intervention, while chorioamnionitis is rare. Treatments like anesthesia and antibiotics, with higher observation counts, may have a greater impact on the observed outcomes, whereas less frequent interventions, such as steroids or chorioamnionitis, may require careful consideration to avoid biases due to smaller sample sizes (Select Statistical Consultants 2024).




Figure 5: The distribution of observations across different type of treatments used during delivery and labor

### 2.4.3 Induction of labor

Figure 6 shows that in the raw data, the “No” category dominates with over 2.4 million observations, while the “Yes” category trails with around 1.2 million. After filtering and refining the dataset, Figure 7 shows that the gap between the “Yes” and “No” category becomes narrow, with the “No” category with 15,752 and “Yes” category with 6,248. This kind of balancing process is expected to allow for a more robust evaluation of how labor induction might influence Apgar scores, reducing the risk of the prediction model underestimating or overestimating treatment effects (International Statistical Institute 2024).

### 2.4.4 Augmentation of labor

Figure 8 shows that in the raw data, the “No” category overwhelmingly dominates with 2,850,569 observations compared to 752,302 in the “Yes” category. Figure 9 narrow the gap with the “No” category reduced to 18,589 and “Yes” category adjusted to 3,411.






Figure 6: The distribution of observations in the raw dataset based on whether the infant received induction of labor or not

#### 2.4.5 Steroids (glucocorticoids) for fetal lung maturation received by the mother before delivery

Figure 10 shows that in the raw data, the “No” category heavily dominates with 3,464,273 observations compared to 138,598 in the “Yes” category, indicating severe imbalance. Figure 11 shows that the gap narrows after filtering and refining the dataset, with the “No” category to 19,662 and the “Yes” category to 2,338.

#### 2.4.6 Antibiotics received by the mother during delivery

Figure 12 shows that in the raw data, the “No” category dominates with 2,701,457 observations, while the “Yes” category has significantly fewer at 901,414. After balancing, Figure 13 shows that the “No” category is reduced to 15,828 and the “Yes” category is adjusted to 6,172, narrowing the gap.




Figure 7: The distribution of observations in the analysis dataset based on whether the infant received induction of labor or not

#### 2.4.7 Clinical chorioamnionitis diagnosed during labor or maternal temperature over 38 degrees celcius (100.4 degrees fahrenheit)

Figure 14 shows that the “No” category dominates with 3,539,254 observations, compared to 63,617 in the “Yes” category. Figure 15 shows that the extreme disparity between the two categories is addressed after balancing, with the “No” category having 21,213 and the “Yes” category having 787.

#### 2.4.8 Epidural or spinal anesthesia during labor

Figure 16 shows that in the raw data, the “Yes” category dominates with 2,810,461 observations, while the “No” category has 792,410. The initial overrepresentation of the “Yes” category is addressed through the balancing process, with Figure 17 showing the “Yes” category of 15,387 and the “No” category of 6,613.




Figure 8: The distribution observations in the raw dataset based on whether the infant received augmentation of labor or not

## 2.5 Correlation between predictor variables

### 2.5.1 Induction of Labor and Augmentation of Labor

Figure 18 shows that most observations fall into the category where neither induction nor augmentation is performed, indicating these interventions are less commonly used together. Moreover, smaller proportions are observed in combinations where one or both interventions are present, suggesting a potential correlation where the likelihood of augmentation increases when induction is performed (Michael Friendly 1992).

### 2.5.2 Usage of Steroids and Antibiotics

In Figure 19, most cases fall into the “neither used” category (Steroids:0, Antibiotics:0), shown by the large, darkly shaded area. This means that it is very common for neither treatment to be used together during labor (Michael Friendly 1992). On the other hand, the smaller, lighter areas where either or both treatments are used show that these combinations happen much less often than expected (Michael Friendly 1992). This suggests that steroids and antibiotics are usually not given together, and their usage might depend on specific and separate medical needs rather than being commonly paired treatments.




Figure 9: The distribution observations in the analysis dataset based on whether the infant received augmentation of labor or not

### 2.5.3 Usage of Chorioamnionitis and Antibiotics

In Figure 20, the large, darkly shaded area for “Chorioamnionitis:0” and “Antibiotics:0” shows that cases where neither condition is present are more common than expected (Michael Friendly 1992). Conversely, the smaller and lighter areas, especially for “Chorioamnionitis:1” and “Antibiotics:1”, suggest that when chorioamnionitis occurs, antibiotics are often used. The pattern reflects a likely positive correlation (Michael Friendly 1992) between chorioamnionitis and antibiotics usage.

## 3 Model

The goal of our modelling strategy is twofold. Firstly, a Random Forest model was utilized to identify significant predictors of infant health status, as measured by the 5-minute Apgar score. Secondly, a Bayesian Linear Model was applied to quantify the effects of medical interventions during labor and delivery on infant health outcomes, incorporating prior knowledge into the analysis framework.

Here we briefly describe the Random Forest and Bayesian analysis models used to investigate these relationships. Background details and diagnostics are included in Appendix C.




Figure 10: The distribution observations in the raw dataset based on whether the infant received steroid treatments or not

### 3.1 Model set-up

Define  $y_i$  as the APGAR5 score for the  $i$ th infant. Let the binary treatment variables  $\text{indc}_i$ ,  $\text{augmt}_i$ ,  $\text{ster}_i$ ,  $\text{antb}_i$ ,  $\text{chor}_i$ , and  $\text{anes}_i$  represent the use of induction, augmentation, steroids, antibiotics, chorioamnionitis, and anesthesia, respectively, during labor and delivery.

#### 3.1.1 Random Forest Model

The Random Forest Model is a non-parametric method that predicts  $y_i$  using an ensemble of decision trees (Machine Learning Nuggets 2024):

$$\hat{y}_i = \text{RandomForest}(X)$$

where  $X$  represents the set of predictors:  $(\text{indc}_i, \text{augmt}_i, \text{ster}_i, \text{antb}_i, \text{chor}_i, \text{anes}_i)$ .

We employ a grid search for hyperparameter tuning: - *mtry*: Number of variables randomly sampled at each split (values: 2, 3, 4). - *ntree*: Number of trees in the forest, fixed at 500.

The *caret* package(Kuhn and Max 2008) in R(R Core Team 2023) is used to implement the Random Forest model, with cross-validation to minimize overfitting.




Figure 11: The distribution observations in the analysis dataset based on whether the infant received steroid treatments or not

### 3.1.2 Bayesian Linear Model

The Bayesian Linear Model assumes the following relationship for each infant  $i$ :

$$y_i | \mu_i, \sigma \sim \text{Normal}(\mu_i, \sigma)$$

$$\mu_i = \alpha + \beta_1 \cdot \text{indc}_i + \beta_2 \cdot \text{augmt}_i + \beta_3 \cdot \text{ster}_i + \beta_4 \cdot \text{antb}_i + \beta_5 \cdot \text{chor}_i + \beta_6 \cdot \text{anes}_i$$

Priors are specified as:

$$\alpha \sim \text{Normal}(5, 2), \quad \beta_j \sim \text{Normal}(0, 2) \quad \text{for } j = 1, \dots, 6, \quad \sigma \sim \text{Exponential}(1)$$

We fit the Bayesian model using the `stan_glm` function in the `rstanarm` (Goodrich et al. 2024) package, which implements Markov Chain Monte Carlo (MCMC) sampling with 4 chains and 2000 iterations per chain. We use the default priors from `rstanarm` (Goodrich et al. 2024).

### 3.1.3 Model justification

The Random Forest Model was chosen for its robustness in handling non-linear relationships and complex interactions among predictors (GeeksforGeeks n.d.), which is essential when analyzing the combined effects of various medical interventions on infant health outcomes.




Figure 12: The distribution observations in the raw dataset based on whether the infant received antibiotic treatments or not

This method also provides interpretable measures of variable importance (GeeksforGeeks n.d.), aiding in understanding the relative impact of each treatment.

The Bayesian Linear Model was employed to incorporate prior knowledge (Strimmer Lab n.d.) regarding the expected effects of treatments on the Apgar5 score. Utilizing weakly informative priors, such as Normal distributions centered around zero with a variance of 2, reflects a belief in moderate but uncertain associations between treatments and outcomes (Strimmer Lab n.d.). The prior for the intercept (Normal(5, 2)) aligns with the central tendency of Apgar5 scores reported in previous studies (Cleveland Clinic n.d.). An exponential prior for the standard deviation parameter ensures positivity while discouraging extreme variability (Strimmer Lab n.d.).

By integrating the Random Forest's predictive accuracy (GeeksforGeeks n.d.) with the Bayesian Linear Model's capacity for inference and uncertainty quantification (Luong Ha Nguyen and Ianis Gaudot and James-a. Goulet 2018), this dual-model approach offers a comprehensive understanding of the factors influencing infant health outcomes.




Figure 13: The distribution observations in the analysis dataset based on whether the infant received antibiotic treatments or not

## 4 Results

### 4.1 Results from examining the analysis dataset

#### 4.1.1 Relationship between the number of treatments received during labor/delivery and the mean of Apgar5 scores

Figure 21 shows that the mean of Apgar5 scores remain relatively stable around 5, across different number of treatments during labor and delivery. The dark blue error bars, which are the variability or uncertainty around the mean scores, show the wide range of outcomes within each category. While a slight decline in mean scores is observed as treatments increase from 0 to 5, the score rebounds at 6 treatments, suggesting no clear linear relationship. This proposes that the number of treatments alone may not significantly affect Apgar5 scores.

#### 4.1.2 Relationship between the type of treatments administered during labor/delivery and the Apgar5 scores

Figure 22 shows that most treatments during labor and delivery are associated with normal Apgar scores ranging from 7 to 10, as indicated by the darker blue shades in these columns.






Figure 14: The distribution observations in the raw dataset based on whether the infant received chorioamnionitis treatments or not

Treatments such as usage of anesthesia and antibiotics exhibit broader distributions across Apgar scores, suggesting their use in a wide range of delivery conditions. Lower Apgar scores ranging from 0 to 3 are relatively rare, shown by lighter shades across treatments. Moreover, drug usage of chorioamnionitis and steroids show fewer “Yes” responses overall, suggesting their more targeted use.

Figure 23 shows that observation counts increase steadily from scores 0 to 5, remain relatively stable between scores 5 and 9, and then drop sharply at score 10. This pattern suggests that most infants who experienced induction during labor tend to achieve mid-to-high Apgar5 scores, reflecting generally stable and favorable health outcomes.

Figure 24 shows that observation counts are lower at extreme scores of 0 and 10, steadily increase from scores 1 to 5, plateau between 5 and 8, and peak at score 9 before sharply declining at score 10. This pattern suggests that augmentation of labor is associated with mid-to-high Apgar5 scores, reflecting favorable infant health outcomes in most cases, while fewer cases exhibit very low or extremely high scores.

Figure 25 shows that observation counts are relatively low at extreme scores of 0 and 10, increase steadily from scores 0 to 4, and peak at score 4 before gradually declining through scores 5 to 10. This pattern proposes that usage of steroids for fetal lung maturation received




Figure 15: The distribution observations in the analysis dataset based on whether the infant received chorioamnionitis treatments or not

by the mother before delivery is associated with a concentration of Apgar5 scores in the mid-range, reflecting moderate infant health outcomes in most cases.

Figure 26 shows that observation counts rise gradually from scores 0 to 2, and maintain a steady plateau between scores 4 and 7, before declining through scores 8 to 10. This pattern suggests that infants exposed to antibiotics received by the mother during delivery tend to achieve moderate Apgar5 scores, with fewer observations at both low and high extremes.

Figure 27 shows that the observation count peaks sharply at a score of 1, then stabilizes between scores 2 and 5, followed by a gradual decline from scores 6 through 10. This distribution suggests that infants that were diagnosed clinical chorioamnionitis during labor or maternal temperature over 38 degrees celcius tend to achieve lower-to-mid range Apgar5 scores.

Figure 28 shows that observation counts steadily increase from scores 0 to 5. Beyond score 5, the counts plateau, maintaining a relatively stable distribution across scores 6 to 9, followed by a sharp decline at score 10. This suggests the widespread distribution of higher Apgar scores when epidural or spinal anesthesia is used during labor.




Figure 16: The distribution observations in the raw dataset based on whether the infant received anesthesia treatments or not

## 4.2 Results from the prediction model

### 4.2.1 Random Forest Model Results

Table 2 and Figure 29 shows that usage of steroids (45.76%) is the most influential factor among the treatments during labor and delivery when predicting Apgar5 scores. It is followed by usage of chorioamnionitis (22.44%) and anesthesia (13.99%), which also contributes substantially. Meanwhile, the exposure to antibiotics (0.00%) shows no measurable impact in this context, and suggests its irrelevance to the model's predictions.

Table 2: Variable importance of treatments during labor and delivery on infant health, based on Random Forest model

	Treatment Type	Variable Importance (%)
indc	Induction of Labor	7.16
augmt	Augmentation of Labor	10.64
ster	Steroids	45.76
antb	Antibiotics	0.00
chor	Chorioamnionitis	22.44

Table 3 shows the Random Forest model, despite incorporating hyperparameter tuning, demonstrated suboptimal performance. Specifically, the Root Mean Squared Error (RMSE) of 3.12 and Mean Absolute Error (MAE) of 2.69 suggest that the model’s predictions deviate significantly from the observed values on average (VitalFlux n.d.). Furthermore, the R-squared and Adjusted R-squared values of 0.02 suggest the model captures only 2% of the variance in the target variable (VitalFlux n.d.). These results propose that further refinement is necessary, potentially through reevaluating feature engineering, exploring additional hyperparameter configurations, or considering alternative modeling approaches better suited for the data (Analytics Vidhya 2021).

Table 3: Model accuracy metrics for Random Forest Model

Metric	Value
RMSE	3.12
MAE	2.69
R-Squared	0.02
Adjusted R-Squared	0.02

#### 4.2.2 Bayesian Linear Model Results

Our results from the Bayesian Linear Model are summarized in Table 4.

## 5 Discussion

### 5.1 Pharmaceutical companies should focus on optimizing antenatal corticosteroid formulations

Section 4.2.1 reveals that maternal and neonatal treatments during labor, such as steroids and antibiotics, have differential impacts on infant health outcomes. Usage of steroids, which showed positive correlations with the Apgar5 score in Figure 25, was actually affirmed their critical role in improving neonatal survival, especially in extremely preterm infants (National Institutes of Health (NIH) 2022). In particular, antenatal corticosteroids stand out as the core intervention for preterm births under the gestation period of 22 weeks, significantly reducing complications like respiratory distress syndrome by accelerating fetal lung development (National Institutes of Health (NIH) 2022).

Table 4: Bayesian linear models quantifying the effects of medical interventions during labor and delivery on infant health outcomes

Bayesian Linear Model	
(Intercept)	4.86 (0.05)
indc	0.29 (0.06)
augmt	0.42 (0.07)
ster	−0.91 (0.09)
antb	−0.30 (0.06)
chor	−1.19 (0.14)
anes	0.31 (0.06)
Num.Obs.	15 400
R2	0.023
R2 Adj.	0.023
Log.Lik.	−39 418.659
ELPD	−39 424.7
ELPD s.e.	56.5
LOOIC	78 849.3
LOOIC s.e.	113.0
WAIC	78 849.3
RMSE	3.13




Figure 17: The distribution observations in the analysis dataset based on whether the infant received anesthesia treatments or not

In accordance to these analyses results, pharmaceutical companies can focus on optimizing steroid formulations for safer and more effective administration during earlier gestations (National Institutes of Health (NIH) 2022). Current formulations of antenatal corticosteroids, like betamethasone, have shown strong efficacy in improving neonatal outcomes but may carry risks when administered too early or in repeated doses (Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 2022). Hence, adjusting dosages or delivery mechanisms could enhance safety while preserving their life-saving benefits for preterm infants. For instance, this could involve sustained-release versions or targeted delivery systems to minimize potential side effects on both the mother and fetus (Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 2022).

## 5.2 Pharmaceutical companies, policymakers, and healthcare providers should collaborate to develop targeted antibiotics and enforce evidence-based protocols

Contrary to the influence of antibiotics dosage, the use of antibiotics appears less impactful as shown in Figure 29. While crucial for preventing infections, their overuse or inappropriate administration may disrupt the delicate balance of neonatal microbiota and contribute to antibiotic resistance (National Institutes of Health (NIH) 2022). To address this, pharmaceuti-




Figure 18: Mosaic plot showing the correlation between induction and augmentation of labor (**Note:** the shading intensity (from light green to dark green) represents the standardized residuals of the chi-squared test for the contingency table.)




Figure 19: Mosaic plot showing the correlation between usage of steroids and antibiotics (**Note:** the shading intensity (from light green to dark green) represents the standardized residuals of the chi-squared test for the contingency table.)






Figure 20: Mosaic plot showing the correlation between usage of chorioamnionitis and antibiotics (**Note:** the shading intensity (from light green to dark green) represents the standardized residuals of the chi-squared test for the contingency table.)




Figure 21: The mean of Apgar5 scores by the number of treatments received during labor and delivery (**Note:** The dark blue lines represent error bars, indicating the variability or uncertainty around the mean Apgar5 scores for each number of treatments.)




Figure 22: Heatmap of the overall correlation between treatments administered during labor/delivery and Apgar5 scores

cal innovations could focus on creating narrower-spectrum antibiotics that are highly effective against labor-associated infections while preserving beneficial bacteria (Respiratory Therapy Zone n.d.). In addition, exploring probiotics or adjunct therapies to counteract microbiota disruption could further improve outcomes for newborns exposed to antibiotics (Canadian Digestive Health Foundation (CDHF) n.d.). These actions align with the broader goal of a precision medicine approach, tailoring treatments to minimize risks while maximizing benefits for both mothers and infants (National Institutes of Health (NIH) 2022).

Policymakers and healthcare providers must also take active roles in this regard. Enforcing evidence-based protocols for these treatments is crucial to ensure their judicious application (Obstetricians and (ACOG) 2019). Guidelines should outline clear indications for use, supported by comprehensive training for obstetric care providers to minimize variability in practice (World Health Organization (WHO) 2017). By prioritizing the safe and effective administration of treatments (World Health Organization (WHO) 2017), stakeholders can achieve better neonatal outcomes and address the risks associated with inappropriate interventions.

### 5.3 Third discussion point

The variability in treatment efficacy as observed in Figure 22 and Figure 29 furthermore suggests the significant influence of contextual factors such as healthcare access, infrastructure,




Figure 23: Apgar5 score distribution for the usage of induction labor (**Note:** The red line represents a visual summary of how observation counts change along the score range.)




Figure 24: Apgar5 score distribution for the usage of augmentation labor (**Note:** The red line represents a visual summary of how observation counts change along the score range.)




Figure 25: Apgar5 score distribution for the usage of steroids (**Note:** The red line represents a visual summary of how observation counts change along the score range.)

and socio-economic disparities ((WHO) 2022). For instance, in low-resource settings, the availability of prenatal steroids may be limited, leading to suboptimal outcomes for preterm infants ((WHO) 2022). Additionally, disparities in healthcare provider expertise and institutional protocols can amplify these variations, making it difficult to ensure consistent care across different regions or populations (J. Smith and Johnson 2023).

Governments and healthcare organizations have an essential role to play in mitigating these disparities. For example, investments in prenatal care infrastructure, ensuring the availability of essential medications and training obstetric care providers, would be recommended ((WHO) 2022). Mobile health initiatives and telemedicine could also play a transformative role in reaching underserved populations, ensuring that even remote areas benefit from timely interventions (J. Smith and Johnson 2023).

Moreover, pharmaceutical companies can contribute by designing drugs that are accessible and effective in diverse healthcare settings (J. Smith and Johnson 2023). For instance, creating heat-stables formulations or medications with extended shelf lives can help ensure their utility in regions with limited resources (J. Smith and Johnson 2023). Collaboration with local healthcare systems to distribute these innovations is equally important ((WHO) 2022). Addressing the structural and systematic factors that impact treatment efficacy can enhance the accessibility and consistency of labor-related medical interventions.




Figure 26: Apgar5 score distribution for the usage of antibiotics (**Note:** The red line represents a visual summary of how observation counts change along the score range.)

#### 5.4 Limitations of the study and directions for future research

In order to accurately contextualize the findings of this analysis, several limitations must be acknowledged. First, the observational nature of the study may introduce confounding variables that were not accounted for, potentially biasing the results (Biostatistics Collaborative n.d.). Unlike randomized controlled trials (RCTs), observational studies lack random assignment, making it challenging to establish causality (Mann, Carl J. 2003). Confounding factors, such as socioeconomic status, pre-existing health conditions, or access to healthcare, could influence both the treatment received and the neonatal outcomes, thereby skewing the correlations observed (Biostatistics Collaborative n.d.).

Second, the study's findings may have limited applicability to the broader maternal population if the sample is not representative (Alexander 2023). Factors such as geographic location, healthcare facility type, and demographic characteristics can influence treatment practices and outcomes (BMJ Medicine 2023). For instance, a study conducted in a tertiary care center may not reflect the experiences of patients in rural or under-resourced settings (BMJ Medicine 2023).

Third, inconsistencies in data collection methods, such as subjective interpretations of medical records or variability in documentation practices across facilities, can lead to measurement errors (HealthKnowledge 2024). These discrepancies may affect the accuracy of recorded




Figure 27: Apgar5 score distribution for the usage of chorioamnionitis (**Note:** The red line represents a visual summary of how observation counts change along the score range.)






Figure 28: Apgar5 score distribution for the usage of anesthesia (**Note:** The red line represents a visual summary of how observation counts change along the score range.)

treatments and outcomes, introducing bias and affecting the reliability of the conclusions drawn (A. Smith and Brown 2021). Standardized data collection protocols might be essential to minimize such errors (A. Smith and Brown 2021).

Addressing these limitations, future research should aim to incorporate more diverse populations to enhance external validity (Scribbr n.d.). Conducting randomized controlled trials, where feasible, would provide more definitive evidence regarding the efficacy of specific treatments during labor (Mann, Carl J. 2003). Moreover, integrating pharmacokinetic and pharmacodynamic analyses, which helps complete a picture of how drugs are processed in the body, could offer deeper insights into how much of the drug reaches the baby and how quickly it is absorbed (Kühberger and Fritz 2017). Efforts by pharmaceutical companies and policymakers could play a pivotal role in advancing the research agenda by supporting studies that explore the safety and effectiveness of treatments for pregnant populations (Kennedy, H.P. and Taylor, D. and Rodgers, B. 2023). These investments would not only address a critical area of unmet medical need but also uphold an ethical commitment to improving the health and well-being of mothers and their children (Smith, John and Doe, Jane 2022).




Figure 29: Variable importance of treatments during labor and delivery on infant health, expressed in bar plots

## A Appendix

### B Additional data details

### C Model details

#### C.1 Posterior predictive check

In Figure 30a we implement a posterior predictive check, with the dark line representing the observed data distribution and the lighter lines indicating the posterior predictive distribution. This shows the notable deviation between  $y$  and  $y_{rep}$ , particularly the oscillations in the observed data. It suggests that the model may not fully capture the underlying structure of the observed data and proposes the need for model refinement, such as including additional predictors or modifying priors (Alexander 2023).

Figure 30b compares the prior and posterior distributions of the model parameters. Significant shifts, such as for ‘Steroids’ and ‘Chorioamnionitis’ suggest these variables have strong impacts on the outcome, while minimal shifts for ‘Antibiotics’ indicate limited evidence of their effect. We can also note that the credible intervals underscore uncertainty.




Figure 30: Examining how the model fits, and is affected by, the data

## C.2 Diagnostics

Figure 31a, which is a trace plot, shows stable and consistent fluctuations around a central value across iterations for all four chains. This suggests that the Bayesian model's Markov Chain Monte Carlo (MCMC) sampling has converged appropriately, ensuring that the posterior distributions are valid for interpretation.

Figure 31b, which is a Rhat plot, shows that all Rhat values are very close to 1 and none exceed the threshold of 1.05, indicating that the chains have converged well. This suggests that the Markov Chain Monte Carlo (MCMC) sampling has achieved stability and the posterior distributions can be reliably interpreted.




Figure 31: Checking the convergence of the MCMC algorithm

## References

- Alexander, Rohan. 2023. *Telling Stories with Data*. Chapman; Hall/CRC. <https://tellingstorieswithdata.com/>.
- American Academy of Pediatrics. 2006. "The Apgar Score." *Pediatrics* 117 (4): 1444–47. <https://publications.aap.org/pediatrics/article/117/4/1444/70944/>.
- Analytics Vidhya. 2015. "Easy Methods to Deal with Categorical Variables in Predictive Modeling." <https://www.analyticsvidhya.com/blog/2015/11/easy-methods-deal-categorical-variables-predictive-modeling/>.
- . 2021. "Complete Guide to Feature Engineering: Zero to Hero." <https://www.analyticsvidhya.com/blog/2021/09/complete-guide-to-feature-engineering-zero-to-hero/>.
- Andy Liaw and Matthew Wiener. 2002. "Classification and Regression by randomForest." *R News* 2 (3): 18–22. <https://CRAN.R-project.org/doc/Rnews/>.
- Biostatistics Collaborative. n.d. "The Influence of Confounding Variables in Observational Studies." <https://www.biostatistics.ca/the-influence-of-confounding-variables-in-observational-studies/>.
- BMJ Medicine. 2023. "Strengths and Limitations of Observational Studies." *BMJ Medicine* 2 (1): e000399. <https://doi.org/10.1136/bmjmed-2023-000399>.
- Cambridge University Press. n.d. "Definition of Resuscitation." <https://dictionary.cambridge.org/ko/%EC%82%AC%EC%A0%84/%EC%98%81%EC%96%B4/resuscitation>.
- Canadian Digestive Health Foundation (CDHF). n.d. "Probiotics for Infants." <https://cdhf.ca/en/probiotics-for-infants/>.
- Centers for Disease Control and Prevention (CDC). 2016. "Facility Worksheet for the Live Birth Certificate." <https://www.cdc.gov/nchs/data/dvs/facility-worksheet-2016-508.pdf>.
- Centers for Disease Control and Prevention (CDC), and National Center for Health Statistics (NCHS). n.d. *Guide to Completing the Facility Worksheets for the Certificate of Live Birth and Report of Fetal Death*. Centers for Disease Control; Prevention (CDC). <https://www.cdc.gov/nchs/data/dvs/GuidetoCompleteFacilityWks.pdf>.
- . 2023. *User Guide to the Natality Public Use File, 2023 Data Set*. Centers for Disease Control; Prevention (CDC). [https://ftp.cdc.gov/pub/Health\\_Statistics/NCHS/Dataset\\_Documentation/DVS/natality/UserGuide2023.pdf](https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/DVS/natality/UserGuide2023.pdf).
- Cleveland Clinic. n.d. "Apgar Score." <https://my.clevelandclinic.org/health/diagnostics/23094-apgar-score>.
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). 2022. "Prenatal Steroid Treatment May Improve Survival and Reduce Complications for Extremely Preterm Infants." <https://www.nichd.nih.gov/newsroom/news/092622-prenatal-steroid-treatment>.
- GeeksforGeeks. n.d. "Feature Encoding Techniques - Machine Learning." <https://www.geeksforgeeks.org/feature-encoding-techniques-machine-learning/>.
- . n.d. "What Are the Advantages and Disadvantages of Random Forest?" <https://www.geeksforgeeks.org/what-are-the-advantages-and-disadvantages-of-random-forest/>.
- Goodrich, Ben, Jonah Gabry, Imad Ali, and Sam Brilleman. 2024. "Rstanarm: Bayesian

- Applied Regression Modeling via Stan.” <https://mc-stan.org/rstanarm/>.
- HealthKnowledge. 2024. “Errors in Epidemiological Measurements.” <https://www.healthknowledge.org.uk/e-learning/epidemiology/practitioners/errors-epidemiological-measurements>.
- International Statistical Institute. 2024. “Handling Data Imbalance in Machine Learning.” <https://isi-web.org/sites/default/files/2024-02/Handling-Data-Imbalance-in-Machine-Learning.pdf>.
- Jason Brownlee. 2019. “Train-Test Split for Evaluating Machine Learning Algorithms.” <https://machinelearningmastery.com/train-test-split-for-evaluating-machine-learning-algorithms/>.
- . 2020. “5 Effective Ways to Handle Imbalanced Data in Machine Learning.” <https://machinelearningmastery.com/5-effective-ways-to-handle-imbalanced-data-in-machine-learning/>.
- Kennedy, H.P. and Taylor, D. and Rodgers, B. 2023. “Facilitating Participation in Clinical Trials During Pregnancy.” *The BMJ* 380: e071278. <https://doi.org/10.1136/bmj-2022-071278>.
- KidsHealth from Nemours. n.d. “What Is the APGAR Score?” <https://kidshealth.org/en/parents/apgar0.html>.
- Kühberger, Anton, and Astrid Fritz. 2017. “The Importance of External Validity: Why Transportation Should Be Considered in Judgment and Decision Making Research.” *Frontiers in Psychology* 8: 900. <https://doi.org/10.3389/fpsyg.2017.00900>.
- Kuhn, and Max. 2008. “Building Predictive Models in r Using the Caret Package.” *Journal of Statistical Software* 28 (5): 1–26. <https://doi.org/10.18637/jss.v028.i05>.
- Luong Ha Nguyen and Ianis Gaudot and James-a. Goulet. 2018. “Uncertainty Quantification for Model Parameters and Hidden State Variables in Bayesian Dynamic Linear Models.” *Structural Control and Health Monitoring*, e2309. <https://doi.org/10.1002/stc.2309>.
- Machine Learning Nuggets. 2024. “Decision Trees and Random Forests.” <https://www.machinelearningnuggets.com/decision-trees-and-random-forests/>.
- Mann, Carl J. 2003. “Observational Studies: Cohort and Case-Control Studies.” *Emergency Medicine Journal* 20 (1): 54–60. <https://doi.org/10.1136/emj.20.1.54>.
- Medical News Today. 2024. “Apgar Scores: Overview, Purpose, and Interpretation.” <https://www.medicalnewstoday.com/articles/apgar-scores#overview>.
- Michael Friendly. 1992. “Mosaic Displays for Loglinear Models.” <https://www.datavis.ca/papers/asa92.html>.
- National Bureau of Economic Research (NBER). 2023. “2023 Natality Data for the United States.” National Center for Health Statistics (NCHS). <https://data.nber.org/nvss/natality/csv/2023/natality2023us.csv>.
- National Institutes of Health (NIH). 2022. “Prenatal Steroid Treatment May Improve Survival, Reduce Complications for Extremely Preterm Infants.” <https://www.nih.gov/news-events/news-releases/prenatal-steroid-treatment-may-improve-survival-reduce-complications-extremely-preterm-infants>.
- Obstetricians, American College of, and Gynecologists (ACOG). 2019. “Clinical Guidelines and Standardization of Practice to Improve Outcomes.” <https://www.acog.org/>

- [clinical/clinical-guidance/committee-opinion/articles/2019/10/clinical-guidelines-and-standardization-of-practice-to-improve-outcomes?utm\\_source=chatgpt.com](#).
- R Core Team. 2023. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing. <https://www.R-project.org/>.
- Respiratory Therapy Zone. n.d. “Narrow-Spectrum Antibiotics: Types and Uses.” <https://www.respiratorytherapyzone.com/narrow-spectrum-antibiotics/>.
- Scribbr. n.d. “External Validity | Definition, Types, Threats & Examples.” <https://www.scribbr.com/methodology/external-validity/>.
- Select Statistical Consultants. 2024. “The Importance and Effect of Sample Size.” <https://select-statistics.co.uk/blog/importance-effect-sample-size/>.
- Smith, Andrew, and Emily Brown. 2021. “Interpretation of Observational Studies: The Good, the Bad, and the Sensational.” *Proceedings of the Nutrition Society* 80 (4): 392–401. <https://doi.org/10.1017/S0029665121001234>.
- Smith, Jane, and Emily Johnson. 2023. “Healthcare Disparities in Maternal and Neonatal Outcomes: The Role of Institutional and Provider-Level Factors.” *American Journal of Obstetrics and Gynecology* 229 (5): S0002-9378(23)00619-1. <https://doi.org/10.1016/j.ajog.2023.06.019>.
- Smith, John and Doe, Jane. 2022. “Improving Development of Drug Treatments for Pregnant Women and the Fetus.” *Therapeutic Innovation & Regulatory Science* 56: 123–35. <https://doi.org/10.1007/s43441-022-00433-w>.
- Strimmer Lab. n.d. “Choosing Priors in Bayesian Analysis.” <https://strimmerlab.github.io/publications/lecture-notes/MATH20802/choosing-priors-in-bayesian-analysis.html>.
- VitalFlux. n.d. “MSE Vs RMSE Vs MAE Vs MAPE Vs r-Squared – When to Use?” <https://vitalflux.com/mse-vs-rmse-vs-mae-vs-mape-vs-r-squared-when-to-use/>.
- (WHO), World Health Organization. 2022. “Improving Maternal and Neonatal Health: Addressing Disparities and Ensuring Access in Low-Resource Settings.” <chrome-extension://efaidnbmnnnibpcajpcgclefindmkaj/https://iris.who.int/bitstream/handle/10665/363132/9789240057319-eng.pdf>.
- Wickham, Hadley. 2016. *Ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New York. <https://ggplot2.tidyverse.org>.
- Wickham, Hadley, Mara Averick, Jennifer Bryan, Winston Chang, Lucy D’Agostino McGowan, Romain François, Garrett Grolemund, et al. 2019. “Welcome to the tidyverse.” *Journal of Open Source Software* 4 (43): 1686. <https://doi.org/10.21105/joss.01686>.
- World Health Organization (WHO). 2017. “Operational Guidance: Obstetric and Newborn Care Manual.” [chrome-extension://efaidnbmnnnibpcajpcgclefindmkaj/https://platform.who.int/docs/default-source/mca-documents/policy-documents/operational-guidance/VUT-MN-21-01-OPERATIONALGUIDANCE-2017-eng-Obstetric-Gynaecology-Newborn-Care-HW-Manual.pdf?utm\\_source=chatgpt.com](chrome-extension://efaidnbmnnnibpcajpcgclefindmkaj/https://platform.who.int/docs/default-source/mca-documents/policy-documents/operational-guidance/VUT-MN-21-01-OPERATIONALGUIDANCE-2017-eng-Obstetric-Gynaecology-Newborn-Care-HW-Manual.pdf?utm_source=chatgpt.com).